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BACKGROUND
The heart failure population is ever expanding, with about 23 million people worldwide 
diagnosed with heart failure. In the United States, acute heart failure (AHF) accounts for 
over one million hospital admissions.1–3 Despite improvements in morbidity and mortality 
for patients with chronic HF with reduced EF due to pharmacological and device based 
therapies, rates of admission, readmission and mortality remain high. Overall, in-hospital 
mortality is relatively low; it is the early post-discharge period, termed the “vulnerable 
phase” (VP), where the greatest number of adverse outcomes occurs. (Figure 1).
The VP begins with an AHF exacerbation and lasts up to 6 months post-discharge. Patients 
who survive this 6-month period following AHF represent a uniform cohort without 
significant variability amongst clinical profiles or systolic blood pressure classifications at 
the time of admission, thus suggesting an end point for the VP.4 This VP period is associated 
with an increased risk of readmission and mortality, with rates of 30% and 10% respectively, 
within the first few weeks.5 Such poor outcomes may be attributed to cardiac factors (such 
as myocardial infarctions, atrial fibrillation, and uncontrolled hypertension), non-cardiac 
comorbidities (such as diabetes, COPD, and infection), patient related factors (medication 
non-adherence, alcohol and substance abuse, dietary indiscretions), and system-based factors 
(such as poor access to discharge follow up).6 Additionally, the VP can be further 
categorized into 3 overlapping subphases: early, middle and late phases. The very early VP 
includes the acute exacerbation and lasts into the first few days post discharge. This was 
evident in the European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) 
registry where 49% of patients admitted in cardiogenic shock died within the first 24 hours 
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following presentation illustrating the importance of early identification of hypoperfusion as 
well as appropriate in-hospital triage of these high risk patients.4 The early VP begins at the 
moment of discharge and readmissions during this time frame have been attributed to both 
patient and system related factors. The later VP takes into account all precipitating factors 
and comorbidities within 6 months of discharge.7 (Table 1) As time progresses following a 
AHF, the readmission and mortality rates gradually decline, as highlighted in the 
Candesartan in Heart Failure: Assessment of Reduction on Mortality and Morbidity 
(CHARM) trial. Odds for mortality declined from six-fold during the first month post 
discharge to two-fold over the time of the trial.8 The susceptibility of patients during the VP 
presents a potential opportunity to improve patient outcomes by altering the trajectory of an 
otherwise poor prognosis.9
AREAS OF UNCERTAINTY
PATHOPHYSIOLOGY OF THE VULNERABLE PHASE
Although there is a significant variability within the AHF population, the pathophysiology of 
the VP can be attributed to numerous contributing factors including the short-term 
worsening of hemodynamics attributed to a failure to relieve congestion during the index 
hospitalization, with progressively increased left ventricular (LV) filling pressures.10, 11 This 
elevation of LV pressure ultimately leads to persistent hemodynamic congestion and long 
term persistent multi-organ injury reflected in abnormalities in markers including troponin 
and creatinine.
Often it is the signs and symptoms associated with congestion that ultimately lead to heart 
failure admissions and subsequent readmissions.12–14 During AHF, intravenous diuretics are 
employed with the goal of lowering elevated filling pressures. Over the course of the 
hospitalization, there is a resolution of symptomatic congestion.5 However, about 20% of 
patients are discharged despite persistent signs and symptoms of HF4. A negligible decrease 
or an increase in body weight suggests a possible failure to relieve clinical congestion during 
index hospitalization, which may potentially contribute to the high post-discharge event rate 
in the ESC-HF-LT registry.4 In the Romanian Acute Heart Failure Syndrome (RO-AHF) 
registry, regardless of age, gender and LVEF, 83% of AHF patients reported their status to be 
improved at discharge.15 However, despite symptomatic improvement, there often remains 
persistent hemodynamic, subclinical congestion at the time of discharge.5
Given the poor hemodynamic reserve commonly seen following a heart failure exacerbation, 
the AHF patient population is exquisitely sensitive to changes in LV filling pressures with 
even the most modest increase potentially leading to worsening of symptoms, worsening 
multi-organ failure, and readmission.10, 11 This cycle of admission and readmission 
ultimately predisposes patients to worse outcomes with poor prognosis as well as an 
increased risk of morbidity and mortality.16
AHF patients often are burdened with numerous comorbidities that contribute to early post 
discharge event rates and predispose this population to AHF during the VP. Addressing both 
cardiac and non-cardiac comorbidities is vital in preventing decompensation during the VP; 
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approximately 40% of deaths and readmissions within 60 days of AHF were secondary to 
non-cardiovascular causes.12
The current culture of medicine, where system based failures predisposes patients to delayed 
care, contributes to the worsening of outcomes during the VP. The inappropriate triage of 
critically ill and complex patients during the very early VP, to hospital facilities or care 
settings poorly equipped to manage them, leaves the patient at risk for worse outcomes 
compared to those who initiated their care at facilities equipped to handle high acuity 
patients.4 The lack of a comprehensive discharge plan, either via difficulty arranging 
immediate outpatient follow up. Lack of resources to pay for medications, follow-up and 
transportation, or poor medical education leaves this population vulnerable for deterioration 
and rehospitalization.
DATA SOURCES
IDENTIFICATION OF PATIENTS AT HIGHEST RISK
Although the VP following AHF is marked by high risk for post-discharge events, there are 
certain subgroups of patients at higher risk than others.17, 18 The identification of these high-
risk groups with the use of emerging prognostic biomarkers as well as risk-stratifying tools 
may allow for targeted treatment of higher risk patients during hospitalization or immediate 
post-discharge period. (table 2).
Natriuretic peptides (NP) levels are amongst the most powerful post-discharge risk 
stratification markers in HF.19, 20 Serial measurements of NP may help identify patients at 
high risk for decompensation during the VP, especially during the transition from 
hospitalization to early outpatient follow up.21 Greene et al. analyzed both baseline and 30 
day post discharge levels of NT-proBNP in the Aliskiren Trial in Acute Heart Failure 
Outcomes (ASTRONAUT) cohort and found that an increased trajectory in NT-proBNP was 
independently associated with cardiovascular mortality (CVM) and AHF (HR 1.14, 95% CI 
1.02–1.26).22 Similarly, when coupled with improvement in clinical congestion, a downward 
trend in NT-proBNP represented an overall lowering risk for HF readmission.23 However, 
the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart 
Failure (GUIDE-IT) study, which followed 894 patients with HFrEF, found that the use of 
NT-proBNP was not useful in predicting the time-to-first AHF or CVM in this population 
(HR 0.98, 95% CI 0.79–1.22; P=0.88).24 The fact that the control arm underwent more 
frequent outpatient visits per year compared to what typically occurs in standard practice 
suggests that more frequent outpatient follow up above usual care improves outcomes. This 
does not imply guided biomarker therapy is better; rather, perhaps more frequent follow up 
of patients is needed.
During AHF, a significant number of patients have elevations in troponin secondary to 
myocardial injury outside of an acute coronary syndrome. The elevation in troponin levels 
has been associated with worsening HF exacerbation, more severe symptoms, greater needs 
for aggressive supportive measures, and worse overall outcomes.25 Analysis of the 
ASTRONAUT cohort found that troponin elevations at the 30-day post discharge mark were 
associated with increased all-cause mortality (ACM) (HR 1.59, 95% CI 1.18–2.13) and 
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cardiovascular mortality/AHF (HR 1.28, 95% CI 1.03–1.58) at 12 months. Assessing 
troponin levels post-discharge identifies patients with long-term persistence of myocardial 
injury; such patients are at the highest risk for readmission and may serve as a complement 
to NP levels in risk-stratification.26
Activation of the RAAS in response to decreased renal blood flow leads to a compensatory 
mechanism aimed at augmenting the inadequate arterial pressure. Consequently there are 
often fluctuations in blood urea nitrogen (BUN) levels during AHF, reflecting both 
congestion and fluid retention.27 Fluctuations in BUN levels during AHF have been 
investigated by numerous trials. Two retrospective analysis suggested BUN could serve as a 
marker of neurohormonal activation even in the presence of renal dysfunction.28, 29 In 171 
patients admitted with AHF, there was a rise in BUN independent of basal renal dysfunction 
thus pointing to the activation of RAAS as the inciting event.29 As with the previous 
markers, decreases in BUN without resolution of clinical congestion were not associated 
with improved outcomes.
Another potential surrogate marker for assessing the underlying risk of AHF patients is 
serum osmolality. In a post-hoc analysis of the EVEREST trial, lower discharge serum 
osmolality was predictive of higher ACM (HR 1.61, 95%CI 1.19–1.75) and those patients at 
the lower spectrum of osmolality demonstrated many features of advanced HF. This marker 
may represent a marker of residual congestion beyond currently available parameters, 
including serum sodium and natriuretic peptides.30
In addition to markers of risk, numerous risk stratification tools have been developed to aid 
in the identification of patients at highest risk based on their position on the VP timeline. 
During the earlier portion of the VP, both the Acute Decompensated Heart Failure National 
Registry (ADHERE) risk tree and the Improving Heart Failure Risk Stratification in the ED 
(STRATIFY) tool may be used to stratify risk.13, 31 Once patients progress to the early VP, 
the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) risk score and 
the Center for Outcome Research and Evaluation (CORE) online readmission risk calculator 
for heart failure can help identify patients at risk for poor outcomes within 7 days of 
discharge and the 30 day all cause readmission rates, respectively. The Get With the 
Guidelines–Heart Failure (GWTG-HF) risk score aids in stratifying patients during the late 
subphase of VP and predicts ACM for future AHF.
Potential Solutions
OPTIMIZING MANAGEMENT
Despite being able to identify markers predictive of worse outcomes, the greatest threat to 
AHF patients is the risk of readmission secondary to persistent congestion.3, 33, 34 The 
primary focus during an AHF hospitalization must be the achievement of both clinical and 
subclinical decongestion. This can only be accomplished by identifying those patients with 
persistent congestion despite clinical improvement. Thus, the assessment and grading of 
congestion prior to hospital discharge remains a crucial opportunity to treat patients who 
have yet to reach optimal euvolemia.34
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PHARMACOLOGIC THERAPIES
Once optimal decongestion has been achieved…
Despite the challenge associated with the management of heart failure with preserved 
ejection fraction due to the lack of life saving therapies, a wide spectrum of medications has 
been shown to reduce mortality in those patients with heart failure and a reduced ejection 
fraction (HFrEF). These medications include beta-blockers, angiotensin converting enzyme 
(ACE) inhibitors, aldosterone receptor blockers (ARBs), aldosterone antagonists, and 
angiotensin receptor-neprilysin inhibitors (ARNIs). Yet despite their proven clinical efficacy, 
the initiation and uptitration of these medications remains suboptimal. Analysis of the 
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart 
Failure (OPTIMIZE-HF) registry revealed that fewer than 10% of the patients were at target 
beta-blocker doses upon discharge with the average beta-blocker dose being less than 50% 
of the target dose.35, 36 Further compounding the problem was the failure to up-titrate 
medications within 90 days post-discharge. Numerous studies, including the Heart Failure: 
A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), Systolic 
Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT), and Cardiac 
Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trials, have demonstrated the overall 
suboptimal dosing of beta-blockers upon discharge.37–39 With regards to ACE inhibitors and 
ARBs, hyperkalemia and renal dysfunction remain the major concerns leading to 
underutilization, with nearly 20% of the eligible HFrEF patients not receiving ACE 
inhibitors or ARBs.40 The utilization of mineralocorticoid receptor antagonists is equally 
poor, with less than a third of eligible patients receiving prescriptions at discharge.41, 42 
Similarly, in the subset of African American population with heart failure intolerant of ACE 
inhibitors, the usage rate of hydralazine with isosorbide dintirate remains below 25% despite 
evidence showing a mortality benefit in this population.43, 44
Digoxin is another underutilized medical therapy that may improve outcomes. While there is 
no mortality benefit associated with its use, digoxin decreases HF hospitalization by 28%.45 
Furthermore, in high-risk patients, defined as New York Heart Association class III-IV 
symptoms, left ventricular ejection fraction <25% or cardiothoracic ratio >55%, digoxin has 
also been showed to reduce the composite of all-cause mortality or hospitalization, while 
withdrawing digoxin therapy leads to an increased risk of heart failure.46, 47 Use of digoxin 
remains controversial however.
The index hospitalization provides an opportune time for both the initiation and appropriate 
uptitration of guideline directed medical therapy (GDMT) in a monitored setting. Studies 
have indicated that initiation and aggressive uptitration of medications prior to discharge 
were associated with a significant reduction in the adjusted risk of death and re-
hospitalization. This was seen in the analysis of beta-blocker usage in eligible patients 
within the OPTIMIZE-HF trial cohort.48 Additionally, an analysis of the metabolic exercise 
test data combined with cardiac and kidney indexes (MECKI) score database suggests 
higher dose beta-blockers were associated with an overall better prognosis compared to 
those on medium and low doses.49 The GWTG-HF registry revealed that patients who were 
continued or newly started on medication prior to discharge had a significantly improved 
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thirty-day mortality in comparison to those not started on therapy with one-year mortality 
was 28.2% for patients continued and 29.7% for patients started on ACEi/ARB compared to 
41.6% for patients discontinued and 41.7% for patients not started on therapy.50
DEVICE THERAPIES
Patients with severe heart failure must be evaluated for implantable cardiac defibrillators 
(ICDs) or cardiac resynchronization therapy (CRT) prior to discharge. While the Danish 
Study to Assess the Efficiency of ICDs in Patients With Non-ischemic Systolic Heart Failure 
on Mortality (DANISH) study raises some questions regarding the use of ICDs in all HFrEF 
patients, ICD therapy remains an integral component in the care of HFrEF patients.51, 52 
CRT provides the added benefit of reverse remodeling, which in turn leads to reductions in 
cardiac volumes, improvements in ejection fractions, and subsequently a reduction in heart 
failure events and mortality.53, 54
NON-PHARMACOLOGIC SYSTEM STRATEGIES
Patient education, home based monitoring (either via the patient or by a visiting nurse 
service [VNS]), and close follow up in multidisciplinary heart failure clinics are all 
additional strategies that serve to address system based factors that potentiate readmissions 
following AHF. Close post-discharge follow up within 1 week of discharge led to fewer 
readmissions at 30 days (risk-adjusted HR 0.85, 95% CI, 0.78–093).55 Additionally, a meta-
analysis of transitional care services such as follow up with home-visiting programs, 
multidisciplinary heart failure clinics and structured telephone support, revealed that these 
interventions result in a reduction in all-cause readmission and mortality at 3–6 months post 
discharge.56 Home visiting programs resulted in a significant reduction in both mortality and 
readmissions (HR of 0.77 and 0.75, respectively), while multidisciplinary heart failure 
clinics had even higher reductions in mortality and readmissions at the 6-month mark (HR 
0.56 and 0.70, respectively). However, there are some conflicting data in regards to ideal or 
best transitional care management. Visiting nurse programs and increased surveillance via 
telemonitoring failed to demonstrate any significant improvement in outcomes.57–60 
Observational data failed to consistently support an outcomes benefit associated with dietary 
modifications towards a salt restricted diet. In fact, in the setting of high diuretic doses, a 
normal sodium diet was shown to reduce rates of renal dysfunction and readmission when 
compared to a low sodium diet.61–63 There are inconsistent impacts on outcomes for other 
interventions such as regular post-discharge telephone calls and the practice of alerting 
outpatient physicians to patient discharge.64
COMORBIDITY OPTIMIZATION
The AHF population frequently has significant cardiac (e.g. atrial fibrillation, ischemia, 
valvular heart disease) and non-cardiac (e.g. diabetes mellitus, sleep disordered breathing, 
chronic lung disease, anemia, depression, chronic kidney disease) comorbidities that 
contribute substantially to early post-discharge event rates. These comorbid conditions and 
their management can directly and indirectly contribute to poor outcomes resulting in 
rehospitalization. Addressing these comorbidities is crucial to improving post-discharge 
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outcomes, especially given that 40% of all deaths and re-hospitalizations within 60 days 
following a HF hospitalization are due to non-cardiovascular causes.12
POTENTIAL FUTURE OPTIONS: MOVING TO THE LEFT
Rather than waiting one to three months per inclusion criteria of SHIFT, EMPHASIS and 
PARADIGM-HF trials, earlier initiation of novel therapies during the index hospitalization 
could potentially medically optimize patients and prevent future AHF. In addition, there are 
other novel therapies currently under investigation that might further reduce post-discharge 
risk among heart failure patients. These include ongoing clinical trials with novel agents 
including a sodium glucose co-transporter 2 inhibitor canagliflozin, a subcutaneous 
natriuretic peptide omecamtiv mecarbil (GALACTIC-HF, NCT02929329) and a sub-
cutaneous guanylate cyclase stimulator vericiguat (VICTORIA, NCT02861534).65–67 The 
Canagliflozin Cardiovascular Assessment Study (CANVAS) found that in patients with 
type-2 diabetes mellitus (T2DM) at high risk for cardiovascular events, treatment with 
canagliflozin lead to an overall reduction in cardiovascular events (HR 0.86, 95%CI 0.75–
0.97) and AHF (HR 0.67, 95%CI 0.52–0.87).68 The findings of the CANVAS trial can 
potentially lead to canagliflozin being included as an adjunct treatment for the large portion 
of the HF population with T2DM, however these findings are yet to be incorporated into the 
ACC/AHA/HFSA guidelines for the management of heart failure.69 Recently, the Chronic 
Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) 
trial demonstrated omecamtiv’s ability to improve cardiac output while simultaneously 
reducing ventricular diameter in patients with chronic HF.66 These novel therapies may 
ultimately prove to be useful tools to help reduce readmissions and mortality in heart failure 
patients during this VP. Appropriate allocation of resources focused on close follow up and 
preventative measures for those at the highest risk of readmission and mortality may also 
provide a unique, patient centered opportunity to escort the AHF population through the 
vulnerable period and into a stable chronic heart failure status.17, 18, 70, 71
CONCLUSION
The VP following AHF is a critical period lasting 6 months post-discharge during which 
there is heightened risk for adverse outcomes. The risk for readmission begins and continues 
throughout hospitalization: Failure to adequately decongest patients and maximize proven 
GDMT prior to discharge or soon after discharge increases risk for adverse events. The 
identification of patients at risk of poor post-discharge outcomes, and the resolution of both 
clinical and subclinical congestion remains the most imperative of goal prior to discharge 
following AHF. Once at decongestive state, proper implementation of heart failure therapies 
and close outpatient follow up will bridge patients through the VP and into a stable, chronic 
heart failure status.
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Figure 1. U-shaped distribution of readmission associated with heart failure management
Rehospitalization risk among patients hospitalized for heart failure. Among patients who 
have repeat hospitalization for heart failure or other cardiovascular-related disease, a three-
phase lifetime readmission risk exists. Red indicates period of highest risk for readmission 
immediately after discharge and just before death. White indicates the lower-risk chronic 
phase where the rate of readmission levels off prior to end of life.
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